3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Breast Neoplasms
19
Neoplasm Metastasis
9
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Carcinoma, Renal Cell
2
Advanced Cancer
2
Unilateral Breast Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Interventions
Cyclophosphamide
32
Filgrastim
18
Irinotecan
15
Topotecan
14
Temozolomide
13
Vincristine
12
Peripheral Blood Stem Cell Transplantation
12
Granulocyte Colony-Stimulating Factor
12
Etoposide
12
Melphalan
11
fludarabine
10
Carboplatin
9
dinutuximab
8
Isotretinoin
8
Interleukin-2
8
Busulfan
8
humanized 3F8 anti-GD2 monoclonal antibody
7
aldesleukin
7
Doxorubicin
7
3-Iodobenzylguanidine
7
sargramostim
6
fludarabine phosphate
6
Vorinostat
6
Zoledronic Acid
5
Stem Cell Transplantation
5
Cisplatin
5
etoposide phosphate
4
Ipilimumab
4
Drug Therapy
4
ribociclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neuroblastoma
×
abemaciclib
×
Clear all
NCT02644460
2023-10-26
AflacST1501
Emory University
Phase 1
Completed
53 enrolled